|
Market Closed -
Australian S.E.
02:10:14 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 167.10 AUD | -1.42% |
|
-4.24% | -3.21% |
| 09-10 | CSL Seqirus Publishes Phase 3 Study Results for Influenza Vaccine | MT |
| 09-09 | Australian shares post six-week closing low as banks drag | RE |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 2.5% | 2.65% | 19.65x | 3.56x | 4.21x | 13.08x | 15.14x | 57.4B | ||
| 0.5% | 0.56% | 18.1x | 2.37x | 4.19x | 9.84x | 11.51x | 78.02B | ||
| -.--% | -.--% | -17.17x | 9.86x | 25.62x | -16.63x | -15.42x | 57.48B | ||
| -.--% | -.--% | 34.47x | 7.11x | 11.73x | 22.49x | 26.18x | 48.81B | ||
| 0.71% | 0.73% | 20.54x | 3.25x | 4.54x | 12.95x | 16.07x | 45.5B | ||
| -.--% | -.--% | 37.49x | 1.74x | 3.54x | 13.51x | 14.73x | 32.08B | ||
| -.--% | -.--% | 54.21x | 4.15x | 3.43x | 26.59x | 23.6x | 24.62B | ||
| -.--% | -.--% | 62.21x | 6.34x | 6.52x | 39.5x | 49.39x | 20.77B | ||
| -.--% | -.--% | 22.98x | 3.38x | 4.94x | 12.86x | 17.87x | 15.75B | ||
| 0.18% | 0.2% | 62.98x | 25.55x | 38.78x | 56.23x | 58.04x | 13.92B | ||
| -.--% | -.--% | -26.83x | -5.26x | 14.96x | -40.16x | -41.46x | 14.16B | ||
| -.--% | -.--% | 22.51x | - | 3.78x | 14.78x | 18.41x | 12.71B | ||
| -.--% | -.--% | -82.53x | 145.84x | 11.81x | -84.78x | -84.4x | 11.56B | ||
| -.--% | -.--% | 45.77x | - | - | - | - | 10.26B | ||
| 2.78% | 3.07% | 12.49x | 1.16x | 1.87x | 7.57x | 9.99x | 6.8B | ||
| 0.36% | 0.41% | 27.6x | - | 7.09x | 22.5x | 24.92x | 5.89B | ||
| -.--% | -.--% | 60.43x | 7.26x | 5.88x | 32.54x | 43.83x | 5.95B | ||
| -.--% | -.--% | -108.72x | - | - | - | - | 4.95B | ||
| Average | 0.39% | 0.42% | 14.79x | 15.45x | 9.56x | 8.93x | 11.78x | 25.92B | |
| Weighted average by Cap. | 0.51% | 0.55% | 18.70x | 8.81x | 9.43x | 9.21x | 11.53x |
- Stock Market
- Stocks
- CSL Stock
- Sector CSL Limited
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
















